ChemotherapyFDA-approvedSecond-line
Cladribine
How it works
Interferes with DNA synthesis, preventing cancer cell growth and division.
Cancer types
Leukemia— All patients
Efficacy
Clinical trials have shown that cladribine can induce complete remission in around 20% of patients, with a median overall survival of approximately 8 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing a Combination of Medications for Relapsed/Refractory T-cell Prolymphocytic Leukemia | Leukemia | phase-1 | — | Source → |
| Testing Cladribine and Venetoclax for Monocytic Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| New Combination Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome | Leukemia | phase-1 | — | Source → |
| Comparing Oral and IV Cladribine for Leukemia Treatment | Leukemia | phase-1 | — | Source → |
| Long-term results of Hairy cell leukemia treatment | Leukemia | phase-2 | A complete response was achieved in 133 of 137 evaluable participants (97%), with 102 (77%) having measurable residual disease negativity. | Source → |
| Cladribine May Increase Risk of Severe Skin Reactions | Leukemia | observational | — | Source → |
| Cladribine Effective for Elderly Hairy Cell Leukemia Patients | Leukemia | observational | The median duration of response for all responders was 119 months. | Source → |
| Hairy Cell Leukaemia Treatment Outcomes in Pakistan | Leukemia | observational | A total of 83.33% of patients who received Cladribine achieved complete remission after 1st line of treatment. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.